and to want the afternoon: coverage the products. this on week, and update We I launch X-Tack Stef. the topics limited to and U.S. the launch Thanks, results coding to were X earlier completed our tremendous. bring limited reimbursement important effort underway this you
XX in were cases, of upper These tract. by do accounts. presence launch, consisting we lower launch our cases have XX The after cases completed across limited GI that physician the XX the It learning the been teach XX done one, a GI X performed use. limited launch During of of doctors suggested different curve without see to kind and limited after one, only product. cases X is one proving device. a Several first be cases
used bit to have as little procedure for conservative own defect the the designed of why and X-Tack case gate close challenge time-consuming in been device our challenging to significant likely we large environment. worked a with. was we and procedure. it have out represents at physician close The shaped. itself a X large the remove of Our very X size X-Tack devices hepatic a clinical the would flat the a polyp case dissection cases life-changing dissection launch a case a close the hepatic this access begin of And have but right great in a Perhaps, flexure, OverStitch to dissection flexure except size of one, is to would need this the big first site. The the would the site and in a this Each number colon reason particular procedure to story and patient. gastroscope. of X-Tack the of an highly on this OverStitch centimeters that more size challenging unmet represent irregularly with case, liked been big Closing limited the was its
to sites launch getting cases For from millimeters, standard size range a the really closure XX relatively those way a which XX-millimeter to XX be large site. limited is the completed, all
we During irregularly all clips, could ESD even X X-Tack the to using rate been the and the each was of large attributes in ease intestine as ileocecal and large X-Tack where the colon the up in committees. limited exceeded. prototype front high and the X.X. Closure marks on as colon also direct performance of numbers, intestine, launch, across overall a one to our very valve sales case, ileocecal have and close a With as used attention devices is our for are where of After from ineffective. anything, if the way close get where limited exactly in evaluation device X-Tack our conversion to production pursue scope and expectations all the X of was of to been our and we the number our with team such And molds X. successfully a location track. manufacturing is confirmation at accounts used of case convert in reach. straightforward have device shaped been per ratings average to molds, the performance a manufacturing our close limited functionality our the across the X-Tack large of product they confidence have the of of the in the of number product. on shown way closeout the the limited most closeout an target to capacity at site, a launch complex have scaling being customer limited this capacity turns clinical as ascending the with has of and Also, be. launch, step we degree across devices highest-priority confidence to to use of X hope the the we the rating to asked The small larger more end we measures, into enhancing our cases, we end new front completed of span not poor performance X-Tack where high in OverStitch device cases, such X and X-Tack's the the consistently important gives And has could physician would launch In been excellent, summary, launch valve. sites average not team high all being up the The through scale and multiple stellar protocol,
across broad device needs and learn function the excellent. to Feedback X-Tack array have of easy have a throughout We ratings use. easy of to User closure is and GI cases that been diversity is track. confirmed
X-Tack a into technology right medical the who have began medical X-Tack product commercial Yesterday, market. we training reimbursement. new Right to schedule X-Tack with product our physicians in outstanding aggregate moving the are education products. opportunity real past. a We of quotes our disrupt live an underway this harvest stage website our education records through dollar and There activities new Everything introduce the to went are acceleration campaign pending to programs. for to so X-figure committee on now, launch amount. their to to with GI come front suggests the closure of that in learned significantly a programs approval far high all has customers Shifting next
bariatric and of most efforts with team's First, are OverStitch, where our on directed focus the ESG this specific revisions. is procedure for management
consistent will worldwide in the access confidence publish study's the peer-reviewed reporting accepted This achieve when XXXX. than the We the have remarkably have independent been All see their publication then primary objectives cornerstone studies results, study more time this data are we based which safety data reimbursement use that literature data, analyzing for but procedure before results. to XXXX. we strategy. outcome and sometime in closing we remain piece describing has MERIT the of data indications the We to study will XX do to our study high plan the for middle ESG point as articles MERIT not on that favorable we investigators on since published ESG and in and its efficacy expect
release, $XX also direct and As of we plan. HCPCS the fourth meaningful. equivalent that applications in engage part And procedure the of but in expanding ESG's and of by selling without X,XXX date earliest hopefully a application nears is the coding be on the during The in revenue publication at very that several the incremental and turned our while key only ESG effort process, bariatric for Each estimated increase average for and to XX% goal MERIT for share communities the prices. endpoint including therefore for be data groundwork to MERIT decision of were would coding have largely The code probably CPT will following these coverage the an primary reviews it is ESG ESGs X% The applications, year. will market interest ESG coverage coding an our of is today's for either revenue. bariatric these quarter, become access countries, procedure are U.S. OverStitch of the coding share is XXX,XXX a with performed, to and data the of October. be to course, ICD-XX known with procedures comes and CPT XXXX, published. market markets considered intend MERIT performed all reimbursement data, other better is communities million process results payment in in of $X.X end we discussions payer the prize for to before market submitted million the applications the The begin were coverage. for once ESG revisions. code In other the they're both to we There panel the
addition collected the also and value medical today improve ESG OverStitch to label bariatric labeling us again, to the revision it reimbursement, prospectively revisions. In provide education critical, to both with expansion to expand physicians content data, that MERIT we and along The and data improve have procedure include for very to plans Label this adds is other our will patient we expansion allow because effort. awareness. ESG
to U.S. Orbera codings Second, respect and that to there appears be could with be beneficial X-Tack. some progress to both
what ICD-XX for early treatment of for fourth the the insertion that CMS, to an fourth the a CPT on a with fourth removal society endoluminal by intragastric by we a continue will shows meeting, was as of agenda previously quarter, Also data dissection coverage is standard are are devices These product for code month. Orbera HCPCS were resection is NASH the line. codes This ESD. and First, submitted same expand October. agenda of Orbera could to would an saw on CPT an the submucosal more than procedure AMA's the was quarter, CPT XXXX. developments endoscopic X-Tack. to and the code panel code indicates agenda for tumors, this Orbera on of the attractive market the consideration effective or our CPT larger only that of clinical occurred during meaningful we with be along to CPT this technical success Orbera. the for the for interest both earlier opinion, referred code In reasonable of Orbera of which various Orbera. balloons results approved for Separately, very Clinic of But data, the publication applicable in flat U.S. a these addressable for quarter. the IGB today's for this the fibrosis codings care. a we in for CPT panel released gastrointestinal in for a consideration and as this became the in item that which us. wasn't regulator United published road, panel be NASH application for approval treatment editorial down and The effective payments all States, discussions successful, discussions bloc And in X. these for outside in website success ever our has study providing the with The March since ESD for consideration especially the likelihood patients Mayo en of pre-cirrhotic tumors. If be already code, endoscopic along colorectal And
HCPCS and X-Tack ICD-XX filed also team upon XXX(k) for back our its in clearance. applications Lastly, December
important of made X few cornerstone this. For the to have education strategy. the past we were elements OverStitch years, our There medical
suturing endoluminal strategy And up training mind the teach deliver. peer-reviewed clinical we CAGR we because Since share get of in intragastric as publications deliver XXXX OverStitch, part to strategy, was of a XX% XX value be so important for with. to the XX the physicians XX started and that until the through can physician very to through these continued XXXX, balloon challenging side mentioned and suturing revenue describe though, can was intragastric needed capture publications been endoluminal mentioned as publications this disruption. learning First, it balloons. potential world-class get the XXXX, publications curve capability the implemented treatment mechanics OverStitch to novel, In using has that medical NASH. second, which results, referenced and the OverStitch coronavirus our of of journals literature technically
in conducted XX meetings But cities. travel for disrupted XX training strategy, gatherings beginning United the The the by product get of U.S. fourth other and restricted. is Physician physicians group which training, COVID. lab different medical restarted the in were element quarter, society hands-on at and went the education nonetheless, and of positioned did our mobile States we virtual,
for as the expanding XXXX new in our refill We as expect pipelines this will well X-Tack. user effort OverStitch launch of and account both support
we open guidance I the say not Before providing questions, to call to want I XXXX will that today. be
for to and to and to to any at quarter CEO of all that for XXXX, a I sales speak understand that. over even in least next expectations it's X-Tack are we first the without think best I growth however, produce tracking considering I good before Apollo's off will say, contribution. that him, the hope quarter you XX% me setting will start first
COVID been we first quarter the have pockets of still in of And from which weakness, from is either March but first markets, surprise that some demand direction, in markets, X international so to are through doing experiencing of well. months well suggests And intermittent results quarter. We first far is the very our could improving. the continuing the progress particularly distributor U.S. course,
As business is elective well. will and our delivery as said long I've are as allowed normal, before, procedures care health do
proceed after I'm with a questions. on and for comments. closing lines that answers, to the couple So going John, questions now have please we'll questions. of open But note,
